Chris Pulling.jpeg

Chris Pulling, Director

Mr. Pulling is CEO of the Ophthalmic Clinical-stage Medical Device start-up MicroOptx and has over 30 years experience in the medical device and clinical and regulatory fields.  MicroOptx has raised approximately $24.5M in capital, including $17M in Q2-2019, and initiated a US pivotal clinical study in Q3-2019.  Chris was previously CEO of The Integra Group, a contract medical research organization he founded in 2002 and later sold to the world's largest contract organization in the medical device sector.  At that time, Integra was assisting over 400 pre-market medical device companies in all aspects of research and development. Chris was personally involved in over 30 original PMA approvals and even more 510(k) clearances. Prior to Integra, he built and ran Medtronic’s Cardiac Rhythm Management's Biostatistics function.  Chris has an MS in Biostatistics from the University of Minnesota and was recently just the fourth recipient of the U of MN’s School of Public Health Alumni Innovator Award.

BOARD OF DIRECTORS

RWarner.png

 

Robert Warner, Director

Mr. Warner is the former President of Alcon Laboratories, a global leader in ophthalmic medical devices, consumer products, and pharmaceuticals. Mr. Warner has extensive international ophthalmic sales and marketing experience, as well as general management, and mergers and acquisitions expertise. He was responsible for Alcon's medical device, pharmaceutical, and consumer products for the US and Canada, and prior to that for Latin America and Canada. Prior to his lengthy tenure at Alcon, he was with Boehringer Ingelheim Pharmaceuticals and Sun Chemical Corporation. Mr. Warner received his BA in Chemistry from Pace University, and his MBA with a concentration in Finance, from Rutgers, The State University of New Jersey.

dr-schwartz-228x300.jpeg

Jay Schwartz, MD, Director

Jay Schwartz, MD is a Board-Certified Ophthalmologist and licensed to practice medicine in Arizona, and is the president of Schwartz Laser Eye Center. Dr. Schwartz was chosen to be the team ophthalmologist for the Phoenix Suns, the Phoenix Mercury, the Arizona Diamondbacks, and the Arizona Coyotes in 2002. Dr. Schwartz graduated from the Chicago College of Osteopathic Medicine. He finished his Ophthalmology Residency at Midwestern University in Chicago, Illinois. He received fellowship training from Charles Casebeer, M.D. 

GCash.png

Gregory D. Cash, Director

Mr. Cash is  President & CEO, of Argent International, a life sciences firm he founded. Prior to this, he was President, CEO, and a director for CardioBility, Inc. And, before that he was President & CEO of BioSig Technologies, Inc. He has over thirty years of business experience and has been a chief executive officer of several companies, both public and privately held, and has run global business units of larger companies.  Previous positions include President and Chief Executive Officer of NeuroTherm, Inc., President and Chief Executive Officer, as well as a director of HeartSine Technologies, Inc., President, Vascular Therapy and New Businesses for Sorin Group based in Milan, Italy, President and Chief Executive Officer and a director of Vasomedical, Inc. a NASDAQ traded public company and spent five years with Boston Scientific Corporation, ultimately as Vice President, Cardiology Sales and Marketing, Europe.  He began his career at Medtronic, Inc., serving fourteen years in increasingly senior sales and marketing positions. 

Brian Mower Pic.jpg

Brian Mower, Director

Mr. Mower joined the i-Lumen Board in January 2021 and currently serves as its Audit Committee Chairman.  Mr. Mower also serves as Vice-Chair on the Arizona Bioscience Industry Association and as Chief Financial Officer of Regenesis Biomedical since 2018.  His career spans 25 years of executive financial leadership with a focus on commercializing innovative medical device technologies.  He was recognized as the 2018 Minneapolis-Saint Paul Business Journal CFO of the year.  Mr. Mower has previously served as CFO for Medibio Limited (ASX:MEB; OTCQB:MDBIF), an Australian public company.  Mr. Mower spent 8 years at Torax Medical (acquired by J&J), an implantable medical device technology, leading finance and international sales operations lleading to the successful acquisition by Ethicon, a J&J company.  Mr. Mower was also CFO of Iomed, Inc. (AMEX:IOX; acquired by ReAble Therapeutics), a publicly-traded drug delivery company,  and EMPI (acquired by DJO Global), a pain management company.  Mr. Mower began his career in the international accounting firm KPMG, is a Certified Public Accountant, and has memberships in the AICPA and UACPA organizations.  He received both Bachelor of Science and Master of Accountancy degrees from Brigham Young University. 

Michael Glover.png

Michael Glover, Director

Mr. Glover has 37 years of experience as an AV-rated lawyer practicing in areas including corporate litigation, securities, corporate governance, insurance, officer and director liability and patent and trademark litigation. Mr. Glover has sat on multiple Boards of corporations and has acted as general counsel on several others, including his role as counsel to i-Lumen for the previous two and a half years. Mr. Glover's extensive legal experience and historical knowledge of i-Lumen and its technology provides a valuable resource for the

i-Lumen Board in its decision making and strategic planning for the future of the company. 

 

KEY MANAGEMENT

JVeLure.png
TDuncan.png
Meredith Mundy.jpg

John VeLure, President & CEO

Mr. VeLure has extensive experience, and a track record of consistent success, as a senior executive and veteran of the medical device and digital healthcare industries.  Most recently, Mr. VeLure was SVP, Corporate Development at Medibio Limited, a publicly-traded, digital health company that provides objective assessment tools for mental health disorders.  Mr. VeLure founded Neurotech NA, Inc., a neurostimulation company that commercialized devices to accelerate non-surgical and post-operative rehabilitation. Serving as its CEO, he completed the sale of Neurotech NA to Theragen in 2015.  Mr. VeLure served as the Senior Director of Marketing and Business Development for Compex Technologies, Inc. managing both a direct and distributor-based sales organization, and securing OEM supplier and product licensing agreements for both the US and international markets.  Prior to this, he was Director of Sales and Marketing for American MedTech, Inc., a Urology company that distributed FDA Cleared, devices for Erectile Disfunction and Incontinence.  Mr. VeLure has a BA double major in Economics and Business Administration from Augustana College in Sioux Falls, SD.

   

      

Thu-Ha Duncan, Engineering & Technology

With over 25 years of experience, Ms. Duncan has a tremendous track record in developing medical devices using electric stimulation to affect physiologically remediative medical treatments for neurologic and muscle therapy indications.  Ms. Duncan also has significant experience in developing innovative products that have met and cleared the FDA requirements as well as international requirements.  As such, she will be a valuable contributor to the company's product development and regulatory clearance process.  Ms. Duncan was formerly the Head of Engineering for Chattanooga Group, Empi, Iomed, and DJO Medical, whose market dominance was in the field of electrical stimulation and therapy.

Meredith Mundy, Clinical Research

Meredith Mundy is the Founder of Paradigm Research LLC and manages i-Lumen's clinical research program.  She has over 20 years of operational management experience in small to large businesses and has focused on clinical operations for early-stage medical device companies during the last 10 years.  These medical devices have included neurostimulation and modulation, ENT applications, systems, software, and implantable devices. Ms. Mundy was most recently with Stryker Corporation, as part of the acquisition of Arrinex, Inc., along with the previous acquisition of Spirox, Inc., where she was she both designed and managed clinical study programs for submissions and post-market surveillance. Meredith brings her highly knowledgeable clinical experience as well as a track record of consistent success, to the company.